Abstract:Carmelo Gurnari, 1, 2 Ishani Nautiyal, 1 Simona Pagliuca 1, 3 1 Department of Translational Hematology and Oncology Research, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA; 2 Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy; 3 ED561 Hematology, Oncogenesis and Biotherapies, University of Paris, Paris, France Correspondence: Carmelo Gurnari Translational Hematology and Oncology Research, Cleveland Clinic Foundation, 9620 Carnegie Ave, Building NE6-250, Cleveland, OH, 44106, USA Email Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder of hematopoietic stem cells genetically defined by the acquisition of somatic mutations in the X-linked phosphatidylinositol glycan anchor biosynthesis, class A ( PIGA ) gene. PIGA is essential for the synthesis of glycosyl phosphatidylinositol (GPI) anchor proteins and its mutations result in a deficiency of such molecules on the membrane of blood cells derived from the mutant clone. In particular, the lack of the GPI-linked complement regulatory proteins CD55 and CD59 is responsible for the increased sensitivity of PNH erythrocytes to complement-mediated destruction. Indeed, the classical clinical picture of PNH includes signs and symptoms of intravascular hemolysis along with variable degrees of cytopenia and a strong tendency to thrombosis, hallmarks of the disease. Before the introduction of anti-complement inhibitors, PNH was characterized by a high mortality primarily due to thrombotic events. The approval of the terminal anti-complement inhibitor eculizumab in 2007 introduced a paradigm shift in the treatment of the disease with improvement of the chronic hemolytic process and dramatic reduction of the thrombotic rate. However, eculizumab has a relatively short half-life when considering a life-long treatment, with obvious consequences as to the quality of life of treated patients necessitating relatively frequent drug administrations. Moreover, up to 30% of PNH patients undergoing eculizumab therapy show a suboptimal response, continuing to require red cell transfusions because of extravascular hemolysis or breakthrough hemolytic episodes. In 2019, the FDA approved the second-generation C5 inhibitor ravulizumab, a long-lasting agent with a better control of disease manifestations. Herein, we discuss the use of ravulizumab in PNH, its differences with first-generation C5 inhibitors, the research evidence supporting the safety and efficacy of this drug and its impact on costs for health systems and quality of life of PNH patients. Keywords: paroxysmal nocturnal hemoglobinuria, ravulizumab, anti-complement therapy Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal stem cell disorder genetically defined by loss-of-function somatic mutations of phosphatidylinositol glycan anchor biosynthesis, class A ( PIGA ) gene (Xq22.2) belonging to the nosological spectrum of bone marrow failure syndromes. 1,2 The picturesque moniker of the disease derives from the classical observation of Coca-Cola colored urine ("hemoglobinuria") during particular changes in bloodstream acid-base equilibrium (i.e., not continuous, "paroxysmal"), typically occurring at night ("nocturnal"). 3 PNH blood cells (erythrocytes, leukocytes and platelets) deriving from the PIGA -mutant clone lack glycosylphosphatidylinositol (GPI)-anchored proteins (in particular CD55 and CD59), which, among others, regulate complement functions. 4 In particular, CD55 inhibits the formation of the C3 and C5 convertases while CD59 prevents the terminal polymerization of the membrane attack complex (MAC) via interaction with C9. Furthermore, the degree of CD55/CD59 deficiency based on immunofluorescent staining distinguishes PNH erythrocytes in type-1 characterized by normal expression, type-2 with partial reduction, and type-3 with their total absence. 4,5 The PNH cells (especially erythrocytes) lacking these GPI-linked moieties are particularly vulnerable to complement-mediated destruction, from which the classical intravascular anemia arises, a hallmark of the disease. 3 Along with anemia, the chronic hemolysis generates a variety of pathophysiological consequences responsible for a thrombophilic state, the other cardinal manifestation of PNH causing high morbidity and mortality when the disease is left untreated. 6 Indeed, the free hemoglobin released after erythrocytes lysis causes a depletion in nitric oxide (NO) into the serum, neutralizing a natural defense that in normal conditions prevents platelets aggregation and adhesion. 7 Besides, other processes are at play in generating the hyperco -Abstract Truncated-

Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria

Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria

Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials

Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations

Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment

Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies

Efficacy and Safety of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis

Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy

The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria

Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up

Paroxysmal nocturnal haemoglobinuria (PNH): novel therapies for an ancient disease

Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis

Biotechnological products for the treatment of complement system disorders including paroxysmal nocturnal hemoglobinuria: currently available and in development

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

Peptide Inhibitors of C3 Activation As a Novel Strategy of Complement Inhibition for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

The complement model disease paroxysmal nocturnal hemoglobinuria

Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors

P782: A Phase 2, Randomized Trial Evaluating The Safety And Efficacy Of Pozelimab And Cemdisiran In Patients With Paroxysmal Nocturnal Hemoglobinuria

Ravulizumab can effectively treat ischemic enteritis caused by paroxysmal nocturnal hemoglobinuria